← Ipsen Biopharmaceuticals, Inc. (IPSEY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ipsen Biopharmaceuticals, Inc. (IPSEY)
Healthcare · market cap $14.0B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Ipsen Biopharmaceuticals (IPSEY) is a mid-cap specialty healthcare company with ~5,400 employees and a market cap of approximately $15 billion. The company fields a broad, multi-indication pipeline anchored by commercialized and late-stage assets in rare endocrine disorders, oncology, and gastroenterology. Near-term catalysts center on Phase 2/3 readouts for Dysport, Cabozantinib, and IPN10200 through year-end 2026 into 2027.
The catalyst path
- 2026-12-15 (est.)Phase 3 · Corabotaseimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EGb761® | Phase 2 | Alzheimer's Disease |
| Lanreotide Autogel® | Phase 3 | Acromegaly |
| Lanreotide (Autogel formulation) | Phase 3 | Acromegaly |
| Odevixibat | Phase 3 | Biliary Atresia |
| Lanreotide PRF | Phase 2 | Acromegaly |
| IPN01195 | Phase 2 | Advanced Solid Tumor |
| nal-IRI | Phase 2 | Pancreatic Cancer |
| IPN60300 | Phase 2 | Locally Advanced Solid Tumor |
| Triptorelin pamoate (embonate) salt | Phase 3 | Advanced Prostate Cancer |
| Elafibranor | Phase 3 | Primary Biliary Cholangitis |
| lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | Phase 3 | Acromegaly |
| Triptorelin Pamoate (Pamorelin® LA 11.25 mg) | Phase 2 | Prostate Cancer |
| BN83495 | Phase 2 | Endometrial Cancer |
| Triptorelin pamoate 11.25mg (Decapeptyl® SR) | Phase 3 | Precocious Puberty |
| Botulinum toxin type A | Phase 3 | Glabellar Frown Lines |
| Triptorelin (I.N.N.) | Phase 3 | Precocious Puberty |
| EGb761 | Phase 3 | Stroke, Acute |
| mecasermin | Phase 3 | Growth Hormone Insensitivity Syndrome |
| Eziclen | Phase 3 | Bowel Cleansing |
| rhIGF-1 (mecasermin) for a period of 86 weeks | Phase 3 | Insulin-Like Growth Factor-1 Deficiency |
Price & technical context
3-month
-9.9%
6-month
-13.1%
12-month
+26.2%
52-wk range
$32.68–$50.70
vs 50-day MA
-8.4%
vs 200-day MA
-6.2%
Realized vol
31.1%
Max drawdown
-19.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IPSEY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.